NVAC Vaccine FinanceWorking Group Update

February 6, 2008

Walt Orenstein, MD

Emory University

Consultant, National Vaccine Program Office

NVAC White Paper

• Goal: The goal is to ensure universal access to all vaccines recommended by the Advisory Committee on Immunization Practices (ACIP) for children and adolescents without financial barriers.

Working Group Membership

- NVAC
 - Gus Birkhead,WG Chair
 - -Jon Almquist
 - Mark Feinberg
 - -Gary Freed
 - -Lance Gordon
 - Calvin Johnson

- Consultants to NVAC
 - Jon Abramson
 - Alan Hinman
 - Jerome Klein
- NVPO
 - Bruce Gellin
 - Angela Shen
 - Emma English
 - Jenny Salesa (U Michigan)

Working Group Membership, cont.

- AHIP Alan Rosenberg
- Nat'l Business Group on Health Liz Greenbaum
- Health Economist Mark Pauley
- Academia Walt Orenstein
- ACIP Dale Morse (Chair)
- NCSL Joy Wilson
- NASMD Barbara Edwards
- U.S. Chamber of Commerce Anthony Wisniewski
- Consumer representative Deborah Wexler
- Agency liaisons
 - CDC Lance Rodewald
 - CMS Jeff Kelman

NVAC Vaccine Finance Working Group Studies Through CDC

- 1. Gary Freed National survey of pediatricians and family physicians looking at private provider attitudes about vaccine financing
- 2. Gary Freed Private practice costs and reimbursement in five states
- 3. Maggie Coleman Vaccine and vaccinationassociated costs and reimbursements in pediatric practices in Georgia

NVAC Vaccine Finance Working Group Studies Through CDC, cont.

4. Judith Glazner – Provider costs and reimbursement for vaccine administration in Denver

5. Peter Szilagyi – Cost of universal influenza vaccination of children in New York State



Take Home Messages



- Wide range of prices
- Wide range of reimbursement
 - Even among most common payer
- Variation is multi-factorial
 - By vaccine
 - By payer
- Large-scale dropout of private providers unlikely at this time

Outline of NVAC Financing Working Group White Paper

- I. Purposes of the paper
- II. Challenges facing childhood and adolescent immunization programs (literature review)
- III. Promise of vaccines
- IV. Current system for financing vaccination of children and adolescents
- V. Review of past reports on vaccine financing
- VI. NVAC Financing Working Group Methods
- VII. Results, Findings, and Stakeholder perspectives
- VIII. Conclusions
- IX. Recommendations

Structure of Conclusions and Recommendations of White Paper

- General conclusions
- Public sector vaccine financing
 - Conclusions
 - Recommendations
 - Not requiring authorizing legislation
 - Requiring legislation
- Public sector vaccine administration financing
- Private sector vaccine financing
- Private sector vaccine administration financing

Timeline for White Paper

- April 1 Public release of white paper including conclusions and recommendations
- April 29-30 Stakeholders' meeting
- May 9 Deadline for public comments
- June 3 Presentation of white paper to NVAC
- Sept 14 Final NVAC vote on recommendations to ASH

Stakeholders' Meeting: Logistics

- April 29-30, 2008
- Tentative location: Rockville, MD
- Notice in Federal Register, end February 2008 will include website for registration
 - NVPO will have blocked rooms; register through website only, not individually
- Major focus: feedback on conclusions and recommendations of white paper
 - Suggested modifications, additions, and deletions

Stakeholders' Meeting: Tentative Agenda

- Presentation of the white paper
- Presentation of five new studies
- Stakeholder feedback
 - Federal, state, and local health departments
 - Employers, payers, and health insurers
 - Vaccine manufacturers
 - Health care providers
 - Vaccine distributors and purchasers
 - Consumers

Next Steps

- Difficulties in achieving consensus
 - Plan: try to reach consensus
 - If unable, NVAC members will vote on conclusions and recommendations to present to full NVAC
 - Provide list of pros and cons for each recommendation
 - Preliminary discussion and recommendations from NVAC at June meeting
 - Final vote at September meeting